NeuroScientific Biopharmaceuticals Ltd. announced significant additions to its Scientific Advisory Board with the appointment of highly experienced clinical ophthalmologist Dr Peter Hnik MD MHSc, and internationally recognised toxicologist and ex-pharma executive Dr Frank Bonner PhD FBTS. Dr Hnik received his medical degree from the Medical Faculty of Charles University of Prague in 1981. After practicing for years at the Eye Clinic of the Charles University Hospital where he performed surgery and consultation in glaucoma and neuro-ophthalmology, Dr. Hnik later joined the Eye Clinic of the University of British Columbia as part of the glaucoma research group. Based in Vancouver, Canada Dr Hnik has until recently served as a Board member and Chief Medical Officer at iCo Therapeutics Inc. and is President of Clinscape Consulting Inc. Dr. Hnik is a member of the Association for Research in Vision and Ophthalmology (ARVO), the American Academy of Ophthalmology (AAO), the European Society of Retina Specialists (EURETINA), the Drug Information Association (DIA), and the New York Academy of Sciences Dr Bonner has over 35 years of experience in toxicology and non-clinical drug development, including as Senior Vice President of Non-Clinical Safety at global pharmaceutical company Sanofi SA. Dr Bonner has comprehensive knowledge of non-clinical safety including all aspects of regulatory guidance, outsourced programme management, mechanistic toxicology, and the application of new technologies to improve predictive screening. Based in the UK, Dr Bonner is a fellow of the British Toxicology Society, Past President of the Society, and has served as a scientific advisor for a number of internationally-based technology and drug development companies.